




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 413/12, A61K 31/42	A1	(11) International Publication Number: WO 95/17401 (43) International Publication Date: 29 June 1995 (29.06.95)
(21) International Application Number: PCT/EP94/04180 (22) International Filing Date: 16 December 1994 (16.12.94) (30) Priority Data: 9326008.1 21 December 1993 (21.12.93) GB (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): GASTER, Laramie, Mary [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB). (74) Agent: SUMMERSELL, Richard, John; SmithKline Beecham, Corporate Intellectual Property, SB House, Great West Road, Brentford, Middlesex TW8 9EP (GB).		(81) Designated States: JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>

(54) Title: DYHYDROBENZOFURANYL-BIPHENYL CARBOXAMIDES HAVING 5HT_{1D} ANTAGONISTIC ACTIVITY



(I)

(57) Abstract

A class of compounds has been discovered and has been found to exhibit 5HT_{1D} antagonistic activity. In the present invention compounds of formula (I) or salts thereof are provided, in which: P is a 5 to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulfur; R¹, R² and R³ are e.g. independently hydrogen, halogen or C₁₋₆alkyl; R⁴ and R⁵ are independently hydrogen or C₁₋₆alkyl; R⁶ and R⁷ are independently hydrogen, C₁₋₆alkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7- membered heterocyclic ring containing one or two heteroatoms selected from oxygen, nitrogen or sulphur; A is CONH or NHCO; B is e.g. -(CH₂)_p or -O(CH₂)_q where p is 2 or 3 and q is 1, 2 or 3; m is 1 to 4; and D is O, S, SO, SO₂, NR¹⁰, CR⁴=CR⁵ or CR⁴R⁵. Processes for the preparation of these compounds and pharmaceutical compositions containing them are also disclosed. The compounds are of use in the treatment of various CNS disorders.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**DIHYDROBENZOFURANYL-BIPHENYL CARBOXAMIDES HAVING 5HT_{1D}
ANTAGONISTIC ACTIVITY**

The present invention relates to novel amide derivatives, processes for their preparation, and pharmaceutical compositions containing them.

- 5 EPA 0 533 266/7/8 disclose a series of benzanilide derivatives which are said to possess 5HT_{1D} receptor antagonist activity. These compounds are said to be of use in the treatment of various CNS disorders.

A structurally distinct class of compounds have now been discovered and have been found to exhibit 5HT_{1D} antagonist activity. In a first aspect, the present invention
10 therefore provides a compound of formula (I) or a salt thereof:



(I)

15

in which

P is a 5 to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur;

- 20 R¹, R² and R³ are independently hydrogen, halogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkenyl, C₁₋₆alkoxy, acyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO₂R⁸, CONR⁹R¹⁰, NR⁹R¹⁰ where R⁸, R⁹ and R¹⁰ are independently hydrogen or C₁₋₆alkyl;

R⁴ and R⁵ are independently hydrogen or C₁₋₆alkyl;

- 25 R⁶ and R⁷ are independently hydrogen, C₁₋₆alkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring containing one or two heteroatoms selected from oxygen, nitrogen or sulphur;

A is CONH or HNCO;

- 30 B is -(CR¹¹R¹²)_p- or -O(CR¹¹R¹²)_q- where R¹¹ and R¹² are independently hydrogen or C₁₋₆alkyl and p is 2 or 3 and q is 1, 2 or 3;

m is 1 to 4; and

D is oxygen, S(O)_n where n is 0, 1 or 2, or D is NR¹⁰ where R¹⁰ is hydrogen or C₁₋₆alkyl, or D is CR⁴=CR⁵ or CR⁴R⁵ where R⁴ and R⁵ are independently hydrogen or C₁₋₆alkyl.

- 35 C₁₋₆alkyl groups, whether alone or as part of another group, may be straight chain or branched.

Suitably P is a 5 to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur. Examples of suitable heterocyclic rings include pyridyl, thienyl, furyl, pyrrolyl, triazolyl, diazolyl, imidazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyridyl, pyrimidyl and pyrazinyl. The heterocyclic
 5 rings can be linked to the remainder of the molecule via a carbon atom or, when present, a nitrogen atom. Preferably P is oxadiazolyl.

Suitably R^1 , R^2 and R^3 are independently hydrogen, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkenyl, C_{1-6} alkoxy, acyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO_2R^8 , $CONR^9R^{10}$, NR^9R^{10} where R^8 , R^9 and R^{10} are
 10 independently hydrogen or C_{1-6} alkyl. Preferably R^1 and R^2 are C_{1-6} alkyl, in particular methyl. Preferably R^3 is hydrogen.

Suitably R^4 and R^5 are independently hydrogen or C_{1-6} alkyl. Preferably R^4 and R^5 are both hydrogen.

Suitably R^6 and R^7 are independently hydrogen, C_{1-6} alkyl, aralkyl, or together
 15 with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring containing one or two heteroatoms selected from oxygen, nitrogen or sulphur. Examples of R^6 and R^7 heterocyclic rings include morpholine, piperazine and piperidine. Examples of R^6 and R^7 aralkyl groups include benzyl. Optional substituents for such rings include C_{1-6} alkyl. Preferably R^6 and R^7 are both
 20 C_{1-6} alkyl, in particular methyl.

Suitably A is CONH or NHCO, preferably A is CONH.

Suitably B is $-(CR^{11}R^{12})_p-$ or $-O(CR^{11}R^{12})_q-$ where R^{11} and R^{12} are
 independently hydrogen or C_{1-6} alkyl and p is 2 or 3 and q is 1, 2 or 3. Preferably B is
 25 $-(CR^{11}R^{12})_p-$ where R^{11} and R^{12} are both hydrogen and p is 2, that is to say, B forms part of a dihydrobenzofuran ring.

Suitably D is oxygen, $S(O)_n$ where n is 0, 1 or 2, or D is NR^{10} where R^{10} is hydrogen or C_{1-6} alkyl, or D is $CR^4=CR^5$ or CR^4R^5 where R^4 and R^5 are independently hydrogen or C_{1-6} alkyl. Preferably D is oxygen, NH or CH_2 .

Suitably m is 1 to 4, preferably m is 2.

30 The group $-D(CR^4R^5)_mNR^6R^7$ can be attached to the phenyl ring at any suitable position. Preferably the group $-D(CR^4R^5)_mNR^6R^7$ is meta to the amide linkage. The groups R^1 , R^2 and R^3 can also be attached at any suitable position.

Particularly preferred compounds of the invention include:

N-[7-[(2-dimethylaminoethyl)amino]-2,3-dihydrobenzofuran-5-yl]-2'-methyl-4'-(5-
 35 methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide,
 N-[7-(2-dimethylamino)ethoxy-2,3-dihydrobenzofuran-5-yl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide,


N-[7-(3-Dimethylaminopropyl)-2,3-dihydrobenzofuran-5-yl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide,
or pharmaceutically acceptable salts thereof.

Preferred salts of the compounds of formula (I) are pharmaceutically acceptable salts. These include acid addition salts such as hydrochlorides, hydrobromides, phosphates, acetates, fumarates, maleates, tartrates, citrates, oxalates, methanesulphonates and p-toluenesulphonates.

Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and the mixtures thereof including racemates. Tautomers and mixtures thereof also form an aspect of the invention.


In a further aspect the present invention provides a process for the preparation of a compound of formula (I) which comprises.

(a) reaction of a compound of formula (II):



(II)

with a compound of formula (III):



(III)

wherein B, D, m, P, R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ are as defined in formula (I) and R¹³ and R¹⁴ contain the appropriate functional group(s) necessary to form the A moiety; and optionally thereafter in any order:

- converting a compound of formula (I) into another compound of formula (I)
- forming a pharmaceutically acceptable salt.

Suitably one of R¹³ or R¹⁴ is an activated carboxylic acid derivative, such as an acyl halide or acid anhydride, and the other is an amine group. Activated compounds of formulae (II) or (III) can also be prepared by reaction of the corresponding carboxylic acid with a coupling reagent such as carbonyldiimidazole, dicyclohexylcarbodiimide or diphenylphosphorylazole. Preferably R¹³ or R¹⁴ is a group COL where L is halo,

particularly chloro.

Compounds of formulae (II) and (III) are typically reacted together in an inert organic solvent such as DMF, THF or dichloromethane at ambient or elevated temperature in the presence of a base such as an alkali metal hydroxide, triethylamine or pyridine.

5 Intermediate compounds of formula (II) can be prepared using standard procedures such as those outlined in EPA 533266/7/8. Intermediate compounds of formula (III) can be prepared using routine chemistry. Certain intermediate compounds of formulae (II) and (III) are novel and form a further aspect of the invention.

10 It will be appreciated to those skilled in the art that it may be necessary to protect certain reactive substituents during some of the above procedures. Standard protection and deprotection techniques can be used. For example, primary amines can be protected as phthalimide, benzyl, benzyloxycarbonyl or trityl derivatives. These groups can be removed by conventional procedures well known in the art.

15 Carboxylic acid groups can be protected as esters. Aldehyde or ketone groups can be protected as acetals, ketals, thioacetals or thioketals. Deprotection is achieved using standard conditions.

20 Certain compounds of formula (I) can be converted into further compounds of formula (I) using standard processes. For example compounds in which R⁶ and R⁷ are both hydrogen or one of R⁶ or R⁷ is hydrogen and the other is C₁₋₆alkyl can be converted to compounds in which R⁶ and R⁷ are both C₁₋₆alkyl using standard alkylation techniques.

25 5HT_{1D} Antagonists, and in particular the compounds of the present invention, are expected to be of use in the treatment of CNS disorders such as mood disorders, including depression, seasonal affective disorder and dysthymia; anxiety disorders, including generalised anxiety, panic disorder, agoraphobia, social phobia, obsessive compulsive disorder and post-traumatic stress disorder; memory disorders, including dementia, amnesic disorders and age-associated memory impairment; and disorders of eating behaviours, including anorexia nervosa and bulimia nervosa. Other CNS disorders include Parkinson's disease, dementia in Parkinson's disease, neuroleptic-induced Parkinsonism
30 and tardive dyskinesias, as well as other psychiatric disorders.

5HT_{1D} Antagonists, and in particular compounds of the present invention, may also be of use in the treatment of endocrine disorders such as hyperprolactinaemia, in the treatment of vasospasm (particularly in the cerebral vasculature) and hypertension, as well as disorders in the gastrointestinal tract where changes in motility and secretion are
35 involved. They may also be of use in the treatment of sexual dysfunction.

Therefore, the present invention, provides a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in therapy.

The present invention also provides a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment of the aforementioned disorders.

In another aspect the invention provides the use of a compound of general formula
5 (I) or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for the treatment of the aforementioned disorders.

In a further aspect the invention provides a method of treating the aforementioned disorders which comprises administering an effective amount to a patient in need of such treatment of a compound of general formula (I) or a pharmaceutically acceptable salt or
10 solvate thereof.

In particular the invention provides a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment or prophylaxis of depression.

It will be appreciated by those skilled in the art that the compounds according to
15 the invention may advantageously be used in conjunction with one or more other therapeutic agents, for instance, different antidepressant agents.

The present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

20 A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable
25 compositions are generally preferred.

Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tableting lubricants, disintegrants and acceptable wetting agents. The tablets may be coated according to methods well known in normal pharmaceutical practice.

30 Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired,
35 conventional flavourings or colorants.

For parenteral administration, fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile

vehicle. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.

The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 1.0 to 200 mg, and such unit doses may be administered more than once a day, for example two or three a day. Such therapy may extend for a number of weeks or months.

The following Examples illustrate the preparation of compounds of the invention.

Description 1**2,3-dihydrobenzofuran-7-carboxylic acid (D1)**

Following the procedure outlined in EP-A-307172, Example 15, 2,3-dihydrobenzofuran
5 (10.73g) was converted to the title compound (D1) (6g, 41%)

¹H NMR (250 MHz CDCl₃)

δ(ppm): 8.76 (brs, 1H), 7.82 (d, 1H), 7.42 (d, 1H), 6.95 (t, 1H) 4.8 (t, 2H), 3.3 (t, 2H)
10

Description 2**7-(trifluoroacetylamino)-2,3-dihydrobenzofuran (D2)**

2,3-dihydrobenzofuran-7-carboxylic acid (D1) (1.42g) was dissolved in a mixture of
15 trifluoroacetic acid (50 ml) and trifluoroacetic anhydride (10 ml). After stirring at room
temperature for 1.5h, the mixture was cooled to 0°C and treated portionwise with sodium
azide (788 mg, 1.4eq.), then stirred at room temperature for 2 days under argon. The
mixture was evaporated under reduced pressure, and the residue partitioned between
CHCl₃ and water. The organic phase was washed with K₂CO₃ (aq), dried (Na₂SO₄) and
20 the solvent evaporated under reduced pressure, to give the title compound (1.64g, 82%) as
an off-white crystalline material.

¹H NMR (250 MHz CDCl₃)

25 δ (ppm): 7.85-8.2 (m, 2H), 7.05 (d, 1H), 6.89 (t, 1H), 4.65 (t, 2H), 3.28 (t, 2H)

Description 3**7-amino-2,3-dihydrobenzofuran (D3)**

30 A solution of 7-(trifluoroacetylamino)-2,3-dihydrobenzofuran (D2) (1.6g) in methanol (30
ml) and 10% NaOH (3 ml) was heated to reflux for 24h. The mixture was evaporated
under reduced pressure and partitioned between ethyl acetate and water. The organic
phase was dried (Na₂SO₄) and the solvent evaporated under reduced pressure to give the
title compound (900 mg, 96%) as a pale orange oil, which crystallised on standing.

35

¹H NMR (200 MHz CDCl₃)

δ (ppm): 6.44-6.75 (m, 3H), 4.57 (t, 2H), 3.55 (br s, 2H), 3.2 (t, 2H)

Description 4

7-amino-5-nitro-2,3-dihydrobenzofuran (D4)

5

Potassium nitrate (8.6g) was added portionwise over ½h to a solution of 7-amino-2,3-dihydrobenzofuran (D3) (10g) in concentrated sulphuric acid (75 ml) at 5-10°C. The resulting solution was stirred for a further 2h, then added to ice, basified with 40% NaOH, and extracted into ethyl acetate. The organic phase was dried (Na₂SO₄) and the solvent
10 evaporated under reduced pressure to give the title compound (10.1g, 76%) as a red/brown foam.

¹H NMR (250 MHz, CDCl₃)

15 δ (ppm): 7.59 (s, 1H), 7.49 (s, 1H), 4.72 (t, 2H), 3.81 (br s, 2H), 3.26 (t, 2H)

Description 5

7-(2-dimethylaminoethyl)amino-5-nitro-2,3-dihydrobenzofuran (D5)

20 A solution of 7-amino-5-nitro-2,3-dihydrobenzofuran (D4) (2g) in ethanol (60 ml) was treated with 2-dimethylaminoethyl chloride hydrochloride (3.36g) and excess sodium carbonate (6g), and heated at reflux for 4 days under argon. The solvent was evaporated under reduced pressure, and the residue partitioned between water and chloroform. The organic phase was dried (Na₂SO₄) and evaporated under reduced pressure to leave an oil
25 which was chromatographed on silica, eluting with methanol and chloroform to give the title compound as a viscous red oil (416 mg, 15%)

¹H NMR (200 MHz, CDCl₃)

30 δ (ppm): 7.55 (s, 1H), 7.35 (s, 1H), 4.73 (t, 2H), 4.5 (br s, 1H), 3.35-3.15 (m, 4H), 2.6 (t, 2H), 2.26 (s, 6H)

Description 6

(5-nitro-2,3-dihydrobenzofuran-7-yl)-(2-dimethylaminoethyl)carbamic acid tert-butyl ester (D6)
35

A solution of 7-(2-dimethylaminoethyl)amino-5-nitro-2,3-dihydrobenzofuran (D5) (416

mg) in dichloromethane (25 ml) was treated with di-tert-butylidicarbonate (433 mg) and triethylamine (0.25 ml), and stirred under argon at room temperature for 24h. The mixture was washed with water, dried (Na_2SO_4), then the solvent evaporated under reduced pressure to leave the title compound (405 mg, 70%).

5

^1H NMR (200 MHz, CDCl_3)

δ (ppm): 8.0 (s, 1H), 7.91 (s, 1H), 4.7 (t, 2H), 3.6 (t, 2H), 3.29 (t, 2H), 2.36 (t, 2H), 2.15 (s, 6H), 1.35 (br s, 9H).

10

Description 7

(5-amino-2,3-dihydrobenzofuran-7-yl)-(2-dimethylaminoethyl) carbamic acid tert-butyl ester (D7)

15 A solution of 5-nitro-2,3-dihydrobenzofuran-7-yl)-(2-dimethylaminoethyl)carbamic acid tert-butyl ester (D6) (387 mg) in ethanol (50 ml) was hydrogenated over 10% palladium on charcoal for 2h at atmospheric pressure and room temperature. The catalyst was removed by filtration and the filtrate evaporated under reduced pressure to give the title compound as a brown oil (260 mg, 73%).

20

^1H NMR (200 MHz, CDCl_3)

δ (ppm): 6.54-6.21 (m, 2H), 4.51 (t, 2H), 3.69 (t, 2H), 3.39-2.99 (m, 4H), 2.5 (t, 2H), 2.28 (s, 6H), 1.44 (br s, 9H)

25

Description 8

7-acetyl-2,3-dihydrobenzofuran (D8)

To a cooled suspension of 2,3-dihydrobenzofuran-7-carboxylic acid (D1)
30 (2 g) in dry diethyl ether (100 ml) was added dropwise under argon, methyllithium (16.2 ml of a 1.5 M solution in diethyl ether). The mixture was stirred at room temperature for 18h, added to 5N hydrochloric acid (50 ml) and extracted into ethyl acetate. The organic phase was washed with potassium carbonate, then water and dried (Na_2SO_4). The solvent was evaporated under reduced pressure to leave the title compound as a plate lemon solid
35 (1.5g, 76%)

^1H NMR (200 MHz, CDCl_3)

δ (ppm): 7.69 (d, 1H), 7.35 (d, 1H), 6.89 (t, 1H), 4.7 (t, 2H), 3.25 (t, 2H), 2.61 (s, 3H).

Description 9

5 7-acetyl-5-nitro-2,3-dihydrobenzofuran (D9)

Using the method outlined in description 4, 7-acetyl-2,3-dihydrobenzofuran (D8) (500 mg) was converted to the title compound as a cream powder (516 mg, 81%)

10 ^1H NMR (250 MHz, CDCl_3)

δ (ppm): 8.65 (s, 1H), 8.2 (s, 1H), 4.91 (t, 2H), 3.36 (t, 2H), 2.65 (s, 3H).

Description 10

15 7-hydroxy-5-nitro-2,3-dihydrobenzofuran (D10)

A solution of 7-acetyl-5-nitro-2,3-dihydrobenzofuran (D9) (500 mg) in chloroform (3 ml) was added to m-chloroperoxybenzoic acid (83 mg) in chloroform (8 ml) containing a catalytic quantity of p-toluenesulphonic acid. A further quantity (83 mg) of the peroxy
20 acid was added after 24h and a further 400 mg after another 24 h. After stirring at room temperature for 3 days under argon, the reaction mixture was washed with sodium bicarbonate solution, dried (Na_2SO_4) and the solvent evaporated under reduced pressure, to give the acetoxy intermediate. This was dissolved in ethanol (50 ml) containing 40%
25 sodium hydroxide (5 ml) and stirred for 30 minutes at room temperature. The mixture was acidified with 5N hydrochloric acid, the solvents were evaporated under reduced pressure, and the residue partitioned between water and chloroform. The organic phase was dried (Na_2SO_4) and the solvent evaporated under reduced pressure. The residue was chromatographed on silica eluting with 60°-80° Petrol-ether and ethyl acetate to give the
title compound (294 mg, 67%).

30

^1H NMR (200 MHz, CDCl_3)

δ (ppm): 7.8-7.67 (m, 2H), 5.59 (br s, 1H), 4.8 (t, 2H), 3.32 (t, 2H).

Description 11**7-(2-dimethylamino)ethoxy-5-nitro-2,3-dihydrobenzofuran (D11)**

A solution of 7-hydroxy-5-nitro-2,3-dihydrobenzofuran (D10) (280 mg) in dimethoxyethane (20 ml) was treated with 2-dimethylaminoethyl chloride hydrochloride (488 mg) and an excess of potassium carbonate (3g), and heated to reflux under argon for 18h. The solvent was evaporated under reduced pressure and the residue partitioned between water and ethyl acetate. The organic phase was dried (Na_2SO_4) and the solvent evaporated under reduced pressure to give a yellow oil. This was dissolved in 5N hydrochloric acid and washed with ethyl acetate. The acidic phase was basified with potassium carbonate and extracted into ethyl acetate. The organic phase was washed with water, and dried (Na_2SO_4). The solvent was evaporated under reduced pressure to leave the title compound as a yellow crystalline material. (284 mg, 73%).

^1H NMR (250 MHz, CDCl_3)

δ (ppm): 7.8 (s, 1H), 7.71 (s, 1H), 4.8 (t, 2H), 4.2 (t, 2H), 3.31 (t, 2H), 2.8 (t, 2H), 2.36 (s, 6H).

Description 12**5-amino-7-(2-dimethylamino)ethoxy-2,3-dihydrobenzofuran (D12)**

Using the method outlined in description 7, 7-(2-dimethylamino)ethoxy-5-nitro-2,3-dihydrobenzofuran (D11) (274 mg) was converted to the title compound (227 mg, 94%)

^1H NMR (200 MHz, CDCl_3)

δ (ppm): 6.25 (s, 1H), 6.17 (s, 1H), 4.51 (t, 2H), 4.19 (t, 2H), 3.95 (br s, 2H), 3.12 (t, 2H), 2.89 (t, 2H), 2.44 (s, 6H)

Description 13**3-Dimethylamino-1-(5-nitro-2,3-dihydrobenzofuran-7-yl)propene-1-one (D13)**

7-Acetyl-5-nitro-2,3-dihydrobenzofuran (D9) (500 mg) was stirred and heated to 80° C for 1h with tert-butoxy-bis (dimethylamino) methane (1.08 ml), then the mixture was cooled and partitioned between Na_2CO_3 and ethyl acetate. The organic phase was dried (Na_2SO_4) and the solvent evaporated under reduced pressure to leave the title compound (0.5g, 80%).

¹H NMR (200 MHz, CDCl₃)

5 δ(ppm): 8.65 (s, 1H), 8.1 (s, 1H), 7.85 (d, 1H), 5.88 (d, 1H), 4.82 (t, 2H), 3.3 (t, 2H),
3.14 (br s, 3H), 2.94 (br s, 3H).

Description 14

1-(5-Amino-2,3-dihydrobenzofuran-7-yl)-3-dimethylaminopropene-1-one (D14)

10 Following the procedure outlined in Description 7, 3-dimethylamino-1-(5-nitro-2,3-dihydrobenzofuran-7-yl)propene-1-one (D13) (500 mg) was converted to the title compound (402 mg, 91%).

¹H NMR (200 MHz, CDCl₃)

15 δ(ppm): 7.8 (d, 1H), 7.08 (s, 1H), 6.69 (s, 1H), 6.01 (d, 1H), 4.58 (t, 2H), 3.41 (br s, 2H),
3.22-2.72 (m, 8H)

Description 15

20 1-(5-Amino-2,3-dihydrobenzofuran-7-yl)-3-dimethylaminopropan-1-one (D15)

A solution of 1-(5-amino-2,3-dihydrobenzofuran-7-yl)-3-dimethylamino-propene-1-one (D14) (400 mg) in dry tetrahydrofuran (9 ml) was added to a stirred suspension of lithium aluminium hydride (46 mg) in dry tetrahydrofuran (9 ml) at 0° C under argon. The mixture was stirred at this temperature for ¼ h then treated sequentially with water (0.046 ml), 10% NaOH (0.068 ml) and water (0.12 ml). After a further ¼ h stirring at room temperature the mixture was filtered through kieselguhr, and washed with dry tetrahydrofuran, and the solvent was evaporated under reduced pressure to give the title compound as a yellow/orange solid (352 mg, 87%).

30 ¹H NMR (250 MHz, CDCl₃)

35 δ(ppm): 7.0 (s, 1H), 6.8 (s, 1H), 4.61 (t, 2H), 3.47 (br s, 2H), 3.21-3.1 (m, 4H), 2.71 (t, 2H), 2.28 (s, 6H)

Description 16**1-(5-Amino-2,3-dihydrobenzofuran-7-yl)-3-dimethylaminopropan-1-ol (D16)**

5 A solution of 1-(5-amino-2,3-dihydrobenzofuran-7-yl)-3-dimethylaminopropan-1-one (D15) (2.5g) in ethanol (200 ml) was treated with sodium borohydride (1.22g) and stirred for 4 h at room temperature. The solvent was evaporated under reduced pressure, and the residue partitioned between water and dichloromethane. The organic phase was dried (Na₂SO₄) and the solvent evaporated under reduced pressure to give the title compound as an orange/red solid (2.12g, 84%).

10

¹H NMR (250 MHz, CDCl₃)

δ(ppm): 6.7 (s, 1H), 6.5 (s, 1H), 5.04-4.95 (m, 1H), 4.56-4.41 (m, 2H), 3.42 (br s, 2H), 3.1 (t, 2H), 2.67-2.41 (m, 2H), 2.29 (s, 6H), 1.91-1.72 (m, 2H).

15

Description 17**7-(3-Dimethylaminopropenyl)-2,3-dihydrobenzofuran-5-ylamine (D17)**

20 A solution of 1-(5-amino-2,3-dihydrobenzofuran-7-yl)-3-dimethylaminopropan-1-ol (D16) (2.12g) in trifluoroacetic acid (60 ml) was refluxed for 10 h, cooled and the solvent evaporated under reduced pressure. The residue was partitioned between 10% Na₂CO₃ and ethyl acetate, the organic phase was dried (Na₂SO₄) and the solvent evaporated under reduced pressure, to give the title compound as an orange foam (2.07g, quantitative).

25

¹H NMR (200 MHz, CDCl₃)

δ(ppm): 6.7-6.3 (m, 4H), 4.56 (t, 2H), 3.7 (d, 2H), 3.15 (t, 2H), 2.72 (s, 6H)

30 Description 18**7-(3-Dimethylaminopropyl)-2,3-dihydrobenzofuran-5-ylamine (D18)**

Following the procedure outlined in Description 7, 7-(3-dimethylaminopropenyl)-2,3-dihydrobenzofuran-5-ylamine (D17) (970 mg) was converted to the title compound (793
35 mg, 81%).

¹H NMR (250 MHz, CDCl₃)

δ (ppm): 6.46 (s, 1H), 6.32 (s, 1H), 4.49 (t, 2H), 3.3 (br s, 2H), 3.11 (t, 2H), 2.58-2.41 (m, 4H), 2.35 (s, 6H), 1.91-1.8 (m, 2H).

5 Example 1

N-[7-[(2-dimethylaminoethyl)amino]-2,3-dihydrobenzofuran-5-yl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide (E1)

10 2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxylic acid (EP 0533 268A1) (106 mg) was heated under reflux in excess thionyl chloride (3 ml) under argon for 1 hr, and the excess thionyl chloride evaporated under reduced pressure. The resulting acid chloride was dissolved in dichloromethane (10 ml) and treated with 5-amino-2,3-dihydrobenzofuran-7-yl)-(2-dimethylaminoethyl)carbamic acid tert-butyl ester (D7) (116
15 mg) and triethylamine (0.06 ml). The mixture was stirred at room temperature overnight then the solvent was evaporated under reduced pressure. The residue was partitioned between aqueous sodium bicarbonate and chloroform, the organic phase was dried (Na_2SO_4) and the solvent evaporated under reduced pressure. The resulting material was dissolved in dichloromethane (20 ml) and stirred with trifluoroacetic acid (4 ml) for 1h at
20 room temperature. The mixture was washed with sodium bicarbonate solution, dried (Na_2SO_4), and the solvent evaporated under reduced pressure, to give a semi-solid which was chromatographed on silica, eluting with methanol and dichloromethane, to give the title compound (24 mg, 13%).

25 ^1H NMR (250 MHz, CDCl_3)

δ (ppm): 8.01 (s, 1H), 7.99-7.9 (m, 3H), 7.85 (s, 1H), 7.45 (d, 2H), 7.35 (d, 1H), 6.97 (s, 1H), 6.76 (s, 1H), 4.58 (t, 2H), 4.43-4.04 (br s, 1H), 3.3-3.15 (m, 4H), 2.68 (s, 3H), 2.59 (t, 2H), 2.35 (s, 3H), 2.28 (s, 6H)

30

Example 2

N-[7-(2-dimethylamino)ethoxy-2,3-dihydrobenzofuran-5-yl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide

35 2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxylic acid (EP 0533 268A1) (166 mg) was heated under reflux with excess thionyl chloride (4 ml) under argon for 1h and the excess thionyl chloride evaporated under reduced pressure. The resulting acid

chloride was dissolved in tetrahydrofuran (15 ml) and treated with 5-amino-7-(2-dimethylamino)ethoxy-2,3-dihydrobenzofuran (D12) (125 mg) in tetrahydrofuran (10 ml) and a solution of sodium hydroxide (45 mg) in water (0.5 ml). The mixture was stirred at room temperature overnight then the solvent was evaporated under reduced pressure. The residue was partitioned between water and dichloromethane, the organic phase was dried (Na₂SO₄) and the solvent evaporated under reduced pressure, to give the crude product. This was chromatographed on silica, eluting with methanol and dichloromethane, to give the title compound as an off-white powder. (124 mg, 45%). m.p. 180-1°C.

¹H NMR (250 MHz, CDCl₃)

δ (ppm): 8.07 (s, 1H), 8.02-7.9 (m, 4H), 7.45 (d, 2H), 7.33 (d, 1H), 7.25 (s, 1H), 7.12 (s, 1H), 4.6 (t, 2H), 4.23 (t, 2H), 3.23 (t, 2H), 2.92 (t, 2H), 2.7 (s, 3H), 2.48 (s, 6H), 2.32 (s, 3H).

Example 3

N-[7-(3-Dimethylaminopropyl)-2,3-dihydrobenzofuran-5-yl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide oxalate (E3)


Following the procedure outlined in Example 2, 2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxylic acid (EP 0533 268A1) (335 mg) and 7-(3-dimethylaminopropyl)-2,3-dihydrobenzofuran-5-ylamine (D18) (250 mg) were converted to the title compound (101 mg, 18%) which was converted to the oxalate salt. Mp 155-8°C.

¹H NMR (250 MHz, CDCl₃) (freebase)

δ(ppm): 8.05-7.9 (m, 5H), 7.58 (s, 1H), 7.49 (s, 1H), 7.44 (s, 1H), 7.35 (d, 1H), 7.1 (s, 1H), 4.58 (t, 2H), 3.22 (t, 2H), 2.68 (s, 3H), 2.6 (t, 2H), 2.51-2.4 (m, 2H), 2.37-2.3 (m, 9H), 1.96-1.8 (m, 2H)

CLAIMS:

1. A compound of formula (I) or a salt thereof:



(I)

in which

- 10 P is a 5 to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur;
 R^1 , R^2 and R^3 are independently hydrogen, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkenyl, C_{1-6} alkoxy, acyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO_2R^8 , $CONR^9R^{10}$, NR^9R^{10} where R^8 , R^9 and R^{10} are independently hydrogen or
 15 C_{1-6} alkyl;
 R^4 and R^5 are independently hydrogen or C_{1-6} alkyl;
 R^6 and R^7 are independently hydrogen, C_{1-6} alkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring containing one or two heteroatoms selected from oxygen, nitrogen or
 20 sulphur;
 A is CONH or HNCO;
 B is $-(CR^{11}R^{12})_p-$ or $-O(CR^{11}R^{12})_q-$ where R^{11} and R^{12} are independently hydrogen or C_{1-6} alkyl and p is 2 or 3 and q is 1, 2 or 3;
 m is 1 to 4; and
 25 D is oxygen, $S(O)_n$ where n is 0, 1 or 2, or D is NR^{10} where R^{10} is hydrogen or C_{1-6} alkyl, or D is $CR^4=CR^5$ or CR^4R^5 where R^4 and R^5 are independently hydrogen or C_{1-6} alkyl.
2. A compound according to claim 1 in which P is oxadiazole.
 3. A compound according to claim 2 or 3 in which R^1 and R^2 are C_{1-6} alkyl.
 30 4. A compound according to any one of claims 1 to 3 in which R^3 is hydrogen.
 5. A compound according to any one of claims 1 to 4 in which A is CONH, B is $(CH_2)_2$ and D is oxygen, NH or CH_2 .
 6. A compound according to any one of claims 1 to 5 in which m is 2 and R^7 and R^8 are both C_{1-6} alkyl.
 35 7. A compound according to claim 1 which is:

N-[7-[(2-dimethylaminoethyl)amino]-2,3-dihydrobenzofuran-5-yl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide,


N-[7-(2-dimethylamino)ethoxy-2,3-dihydrobenzofuran-5-yl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide,

- 5 N-[7-(3-Dimethylaminopropyl)-2,3-dihydrobenzofuran-5-yl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide,

or a pharmaceutically acceptable salt thereof.

8. A process for the preparation of a compound of formula (I) which comprises
(a) reaction of a compound of formula (II):


10



(II)

with a compound of formula (III):

15



(III)

- 20 wherein B, D, m, P, R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ are as defined in formula (I) and R¹³ and R¹⁴ contain the appropriate functional group(s) necessary to form the A moiety; and optionally thereafter in any order:

- converting a compound of formula (I) into another compound of formula (I)
- forming a pharmaceutically acceptable salt.

- 25 9. A compound according to any one of claims 1 to 7 for use in therapy.

10. A pharmaceutical composition which comprises a compound according to any one of claims 1 to 7 in association with a pharmaceutically acceptable carrier or excipient.

INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/EP 94/04180

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D413/12 A61K31/42

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 533 268 (GLAXO GROUP LIMITED) 24 March 1993 cited in the application see abstract; claims ----	1-10
A	EP,A,0 533 266 (GLAXO GROUP LIMITED) 24 March 1993 cited in the application see claims ----	1-10
P,A	GB,A,2 276 164 (GLAXO GROUP LIMITED) 21 September 1994 see abstract; claims -----	1-10

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

23 February 1995

Date of mailing of the international search report

- 9. 03. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Paisdor, B

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 94/04180

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0533268	24-03-93	AP-A- 303	28-01-94
		AU-B- 656021	19-01-95
		AU-A- 2453092	25-03-93
		CA-A- 2078505	19-03-93
		HU-A- 65608	28-07-94
		JP-A- 6116251	26-04-94
		US-A- 5340810	23-08-94
		CN-A- 1076195	15-09-93
EP-A-0533266	24-03-93	AU-A- 2452992	25-03-93
		CA-A- 2078506	19-03-93
		HU-A- 66319	28-11-94
		JP-A- 6107649	19-04-94
		US-A- 5356893	18-10-94
GB-A-2276164	21-09-94	NONE	